Amid growing concern of the overuse and misuse of obesity drugs, the UK’s pharmacies regulator rolled out stricter guidelines ...

The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an ...

A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...

BioWorld recorded 212 clinical trial updates, an increase from 180 in November and closely aligning with 219 in October. The month saw 16 successful phase III outcomes, along with two mixed results ...

The week's investing action plan includes a strong dose of pharma and biotech earnings, January econ reports, plus Amazon and ...

Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...

The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...

A physician and entrepreneur with over 30 years of life sciences experience, Dr. Pruzanski previously served as Chairman and CEO of Versanis Bio (acquired by Eli Lilly) and was the founder and CEO ...

Vijay Pande, PhD, founding investor of Andreessen Horowitz's Bio + Health fund and a general partner with the tech venture capital firm , discusses how AI’s uptake in healthcare will shape its ...

Eli Lilly has its sights set on a candidate with a different mechanism of action that it hopes to acquire via a $1.93 billion takeover of US biotech Versanis Bio. Versanis’ main asset is ...

K-Bio leaders pursue U.S. factories and conferences during Lunar New Year K-Bio executives opt for international business ...

Aktis Oncology, an oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for ...